Drug intelligence / Profile preview

BTL-TML-COVID

Development stage: Phase 2
Lead developer: Beech Tree Labs
Modality: Device-based Delivery → Drug Delivery Systems
Administration: Sublingual

Overview

BTL-TML-COVID is a low-dose thimerosal formulation developed by Beech Tree Labs for the treatment of COVID-19 symptoms. It's administered sublingually (under the tongue) and has undergone FDA-authorized clinical trials to evaluate its safety and efficacy. The drug works by inhibiting viral replication while also modulating the immune response. In vitro studies show it downregulates pro-inflammatory genes such as those coding for INF-alpha, IL-1, and GM-CSF, which helps dampen the cytokine storm associated with severe COVID-19 symptoms.

Other names: Thiomersal

Targets

GM-CSF (Granulocyte-macrophage colony-stimulating factor)IL1A (Interleukin 1 alpha)IFN-α (Interferon alpha-7)

Beyond the preview

Go deeper on BTL-TML-COVID.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTL-TML-COVID.